We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

SEC Filings

Form 424B5
AC IMMUNE SA filed this Form 424B5 on 07/19/2018
Document Outline
Entire Document (809.1 KB)
Subdocument 1 - 424B5 - FORM 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - AC Immune SA
Page 8 - Our Strategy
Page 9 - N/A
Page 10 - Corporate Information
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - Risks Related to Our Common Shares, the Public Offering and the First Rights Offering
Page 17 - Shareholders may not have been able to exercise pre-emptive subscription rights.
Page 18 - There is only a limited free float of our common shares; this may have a negative impact on the liqu
Page 19 - We do not expect to pay dividends in the foreseeable future.
Page 20 - U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our
Page 21 - Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit ou
Page 22 - Shareholders in countries with a currency other than Swiss Francs face additional investment risks f
Page 23 - We may lose our foreign private issuer status, which would then require us to comply with the Exchan
Page 24 - As a result of being a public company we incur additional costs and we may not manage to comply with
Page 25 - Although we believe that we were not a passive foreign investment company, or PFIC, for U.S. federal
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - The First Rights Offering
Page 31 - The Offered Shares
Page 32 - The Second Rights Offering
Page 33 - N/A
Page 34 - Swiss Tax considerations
Page 35 - Taxation in respect of Offered Shares
Page 36 - Swiss income taxes
Page 37 - International Automatic Exchange of Information
Page 38 - Taxation of Distributions
Page 39 - Passive Foreign Investment Company Rules
Page 40 - Information Reporting and Backup Withholding
Page 41 - Commission and Expenses
Page 42 - Option to Purchase Additional Shares
Page 43 - N/A
Page 44 - N/A
Page 45 - Stabilization
Page 46 - Disclaimers About Non-U.S. Jurisdictions
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - TABLE OF CONTENTS
Page 53 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 54 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 55 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 56 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 57 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 58 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 59 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 60 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 61 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 62 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 63 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 64 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 65 - Investing in our securities involves risks. See Risk Factors beginning on page 4 of this prospectus.
Page 66 - N/A
Page 67 - Neither the delivery of this prospectus nor any sale made under it implies that there has been no ch
Page 68 - N/A
Page 69 - N/A
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - Common Shares